11-08-2025
Leading ED specialist joins LTR Pharma's US advisory
Leading US erectile dysfunction specialist Dr Amy Pearlman to join LTR Pharma scientific advisory board
Appointment supports launch of ROXUS in H1 CY26 with Pearlman to advise on medical education and prescriber engagement strategies
Special Report: LTR Pharma has announced a key appointment to its scientific advisory board as it gears up to launch its innovative nasal spray-mist to treat erectile dysfunction (ED) products in the US.
Strengthens US market entry capabilities for Roxus and SPONTAN, targeting the US$3.7 billion erectile dysfunction market
US board-certified urologist and nationally recognised leader in sexual medicine Dr Amy Pearlman has joined the LTR Pharma (ASX:LTP) scientific advisory board.
As a member of the board Pearlman will provide strategic clinical insight, medical engagement, and market access strategies for SPONTAN and ROXUS, the company's nasal spray treatments for ED.
Pearlman is co-founder of Prime Institute in Coral Gables, Florida, which is a premium private medical practice focused on optimising cardiometabolic, hormonal, and sexual health in men and women.
She is a former director of the Men's Health Program at the University of Iowa and a fellowship-trained specialist in male sexual and hormonal health.
Pearlman has trained at leading US medical institutions and built a distinguished career in sexual medicine, serving on boards and editorial panels for major professional bodies including the Sexual Medicine Society of North America and Urology Times.
An active member of the American Urological Association, she specialises in both medical and surgical management of a range of sexual health conditions for both men and women.
As a prominent voice in sexual health innovation LTR Pharma said Pearlman bought extensive expertise in ED treatment, testosterone optimisation, and comprehensive approaches to sexual wellness.
She has contributed to the Fifth International Consultation on Sexual Medicine (ICSM 2024), shaping global policy and recommendations in sexual health alongside leading international experts.
Bolstering clinical expertise for US push
Pearlman's appointment significantly enhances LTR Pharma's clinical expertise as it prepares for expansion into the US market with a deep understanding of the American healthcare landscape.
The company said her established relationships with key opinion leaders, and a proven record in advancing innovative treatments would be instrumental in positioning SPONTAN and Roxus for success in North America.
Pearlman is set to play a pivotal role in building prescriber awareness for the company's rapid-onset ED treatments.
Her thought leadership is widely recognised through national media appearances, conference presentations, and her popular podcast Pearls and Perspectives.
Pearlman has been honoured with international professorships and is frequently invited as a keynote speaker at major urological and sexual medicine conferences globally.
'Compelling alternative' to current treatments
Pearlman said she believed SPONTAN and ROXUS would be important additions to treatment options in the US for men seeking effective, rapid-onset ED treatment.
'The intranasal delivery platform offers a compelling alternative to current oral medications, providing onset of action in 10 minutes or less with an excellent safety profile,' she said.
'Having dedicated my career to advancing sexual health and wellness, I'm thrilled to join LTR Pharma's scientific advisory board and contribute to bringing these innovative treatments to American patients who deserve better options for spontaneous intimacy."
LTR Pharma executive chairman Lee Rodne said the company was honoured to welcome Pearlman to its scientific advisory board.
'Her recognised expertise in sexual medicine, combined with her innovative approach to patient care and treatment, makes her an invaluable addition to our team.
Rodne said Pearlman's appointment is a critical milestone in the company's US market entry strategy, with ROXUS planned for launch in H1 CY26.
'Her relationships with prescribers and her influential position within the American urological and sexual health community will be crucial as we build momentum in the world's largest pharmaceutical market,' he said.
'Her appointment underscores our commitment to assembling world-class expertise to deliver innovative treatments for erectile dysfunction."
This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
